Questões de Concurso Para fiscal

Foram encontradas 7.955 questões

Resolva questões gratuitamente!

Junte-se a mais de 4 milhões de concurseiros!

www.qconcursos.com
Q2242040
Contabilidade Geral Balanço Patrimonial , Critérios de Avaliação dos Bens Patrimoniais ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242040 Contabilidade Geral
A empresa Albatroz tem em seu parque industrial capacidade instalada para processar o equivalente a 4 toneladas de fertilizantes agrícolas ao mês. Esta capacidade, ao longo dos últimos 5 anos, tem se mostrado superior em 10% ao que regularmente a empresa processa. No último exercício, em virtude de uma anormal crise econômica no país no qual a empresa opera, sua produção tem sido 25% abaixo da sua capacidade instalada. Se a empresa opera com uma ociosidade de 25% em relação a sua capacidade instalada, pode-se concluir que 10% é a sua ociosidade normal e os 15% restantes é a sua capacidade ociosa excedente.
Levando em consideração o que anteriormente foi exposto, a capacidade ociosa deve sofrer o seguinte tratamento contábil:
Alternativas
Q2242039
Contabilidade Geral Demonstração do Resultado do Exercício ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242039 Contabilidade Geral
Na elaboração das Demonstrações Consolidadas, o valor correspondente a resultados não realizados deve ser
Alternativas
Q2242038
Contabilidade Geral Balanço Patrimonial , Dividendos ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242038 Contabilidade Geral
A distribuição de dividendos efetuada por companhia controlada ocasiona na controladora
Alternativas
Q2242037
Contabilidade Geral Balanço Patrimonial , Provisões, Passivos Contingentes e Ativos Contingentes ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242037 Contabilidade Geral
A existência de ônus reais sobre os elementos dos ativos e de fatos contingentes, cujo valor ou probabilidade for de difícil mensuração, devem ser
Alternativas
Q2242036
Contabilidade Geral Balanço Patrimonial , Patrimônio Líquido ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242036 Contabilidade Geral
Identifique nas afirmações a seguir aquela que NÃO é verdadeira.
Alternativas
Q2242035
Contabilidade Geral Balanço Patrimonial , Amortização, Depreciação e Exaustão ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242035 Contabilidade Geral
Instruções: Utilize as informações a seguir para responder à questão. 


     A Cia Lance Alto, em 31.12.20x1, possuía em seus ativos uma máquina industrial cujo custo histórico era de R$ 10 milhões e a respectiva depreciação acumulada correspondia a 80% desse valor. Em 02.01.20x2, ao registrar a reavaliação desse item, adiciona à conta de Máquinas e Equipamentos o valor de R$15 milhões, de acordo com o laudo de avaliação, o qual também indica como vida útil remanescente do bem em questão 5 anos.
Em 31.12.20x2, para registrar a reavaliação desse ativo, a empresa deve utilizar o procedimento contábil de
Alternativas
Q2242034
Contabilidade Geral Balanço Patrimonial , Amortização, Depreciação e Exaustão ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242034 Contabilidade Geral
Instruções: Utilize as informações a seguir para responder à questão. 


     A Cia Lance Alto, em 31.12.20x1, possuía em seus ativos uma máquina industrial cujo custo histórico era de R$ 10 milhões e a respectiva depreciação acumulada correspondia a 80% desse valor. Em 02.01.20x2, ao registrar a reavaliação desse item, adiciona à conta de Máquinas e Equipamentos o valor de R$15 milhões, de acordo com o laudo de avaliação, o qual também indica como vida útil remanescente do bem em questão 5 anos.
O valor a ser registrado como depreciação do ano de 20x2 seria:
Alternativas
Q2242033
Contabilidade Geral Demonstração do Resultado do Exercício , Receitas, Despesas e Apuração do Resultado do Exercício ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242033 Contabilidade Geral

Instruções: Utilize as informações a seguir para responder à questão.


I. Os registros contábeis da Cia Miramar, empresa de capital aberto, acusam uma operação de financiamento de importação de máquinas, contratada em 01.07.20x0 no valor de US$ 10.000.000, pelo prazo de 10 anos, carência de 5 anos e juros semestrais de 3% a.s. pagáveis no último dia útil do mês de vencimento.


II. A flutuação do dólar de 01.07.20x0 a 31.12.20x1 foi: 



Os juros incidentes no contrato de financiamento devem ser
Alternativas
Q2242032
Contabilidade Geral Outras Demonstrações , Demonstração de Origens e Aplicações de Recursos – DOAR ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242032 Contabilidade Geral

Instruções: Utilize as informações a seguir para responder à questão.


I. Os registros contábeis da Cia Miramar, empresa de capital aberto, acusam uma operação de financiamento de importação de máquinas, contratada em 01.07.20x0 no valor de US$ 10.000.000, pelo prazo de 10 anos, carência de 5 anos e juros semestrais de 3% a.s. pagáveis no último dia útil do mês de vencimento.


II. A flutuação do dólar de 01.07.20x0 a 31.12.20x1 foi: 



Na elaboração da Demonstração de Origens e Aplicações de Recursos da empresa em 31.12.20x0, o procedimento técnico utilizado quanto ao valor a ser registrado na rubrica Despesas de Correção Cambial será:
Alternativas
Q2242031
Contabilidade Geral Outras Demonstrações , Notas Explicativas na Contabilidade Geral ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242031 Contabilidade Geral
Uma determinada empresa realiza uma operação de aquisição de 15.000.000 ações de sua própria emissão. Esse evento contábil deverá ser
Alternativas
Q2242030
Contabilidade Geral Legislação de Contabilidade , Normas CFC - CPC ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242030 Contabilidade Geral
São alternativas para avaliar ativos a valores de saída:
Alternativas
Q2242029
Contabilidade Geral Demonstração do Resultado do Exercício , Receitas, Despesas e Apuração do Resultado do Exercício ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242029 Contabilidade Geral
 O consumo de ativos ligado direta ou indiretamente à obtenção da receita é denominado
Alternativas
Q2242028
Contabilidade Geral Outras Demonstrações , Demonstrações das Mutações do Patrimônio Líquido - DMPL ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242028 Contabilidade Geral
O aumento do Capital Social com utilização de saldos de Reservas de Lucros e Lucros/Prejuízos Acumulados é
Alternativas
Q2242027
Contabilidade de Custos Custo de Produção , Custo Primário ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242027 Contabilidade de Custos
São classificados como custos primários
Alternativas
Q2242026
Contabilidade Geral Balanço Patrimonial , Critérios de Avaliação dos Bens Patrimoniais ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242026 Contabilidade Geral
As peças de reposição de equipamentos que possuam disponibilidade normal no mercado, vida útil e valor econômico não vinculados à vida útil e ao valor econômico do equipamento original devem ser classificadas como
Alternativas
Q2241614
Inglês Interpretação de texto | Reading comprehension ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241614 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
According to the text,
Alternativas
Q2241612
Inglês Interpretação de texto | Reading comprehension ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241612 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
Segundo o texto, a NeuroNova
Alternativas
Q2241608
Inglês Sinônimos | Synonyms ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241608 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
A synonym for odd would be: 
Alternativas
Q2241605
Inglês Sinônimos | Synonyms ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241605 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
Para responder à questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado (....60....). 
Alternativas
Q2241604
Inglês Interpretação de texto | Reading comprehension ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241604 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
Para responder à questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado (....59....). 
Alternativas
Respostas
1701: B
1702: C
1703: E
1704: A
1705: C
1706: B
1707: D
1708: A
1709: A
1710: C
1711: A
1712: D
1713: E
1714: E
1715: B
1716: D
1717: E
1718: E
1719: B
1720: A
www.qconcursos.com